Consolidation anti-CD22 fractionated radioimmunotherapy with Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Date publication

janvier 2017

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DAGUINDAU Etienne

Tous les auteurs :
Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27964867

Résumé

Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma.

Mots clés

Aged, Antibodies, Monoclonal, Humanized, therapeutic use, Antibodies, Monoclonal, Murine-Derived, therapeutic use, Antineoplastic Agents, Immunological, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cyclophosphamide, therapeutic use, Doxorubicin, therapeutic use, Female, Humans, Lymphoma, Large B-Cell, Diffuse, drug therapy, Male, Middle Aged, Prednisone, therapeutic use, Prospective Studies, Radioimmunotherapy, methods, Sialic Acid Binding Ig-like Lectin 2, antagonists & inhibitors, Treatment Outcome, Vincristine, therapeutic use, Yttrium Radioisotopes, therapeutic use

Référence

Lancet Haematol. 2017 Jan;4(1):e35-e45